Outcome	No. of studies	No. of participants	Statistical method	Effect size	Vaccine efficacy (95% CI)
Confirmed SARS‐CoV‐2 infection after complete vaccination	N/A	N/A	N/A	N/A	N/A
Confirmed symptomatic COVID‐19 after complete vaccination	1	18,695	N/A	N/A	91.10% (83.80% to 95.10%)
Severe or critical COVID‐19 after complete vaccination	1	19,866	N/A	N/A	100.00% (94.40% to 100.00%)
All‐cause mortality	1	21,862	Risk Ratio (M‐H, Random, 95% CI)	0.99 (0.10 to 9.54)	N/A
Serious adverse events	1	21,862	Risk Ratio (M‐H, Random, 95% CI)	0.65 (0.39 to 1.07)	N/A
Systemic reactogenicity events	N/A	N/A	N/A	N/A	N/A
Any adverse event	N/A	N/A	N/A	N/A	N/A
Local reactogenicity events	N/A	N/A	N/A	N/A	N/A